Taizhou Crene Biotechnology Co., Ltd.
                                                                                                           
Verified Supplier
19 Years
Since 2007
Menu
Chemicals Organic Intermediate

Sunitinib rtk inhibitor C Kit Inhibitors Cas 557795-19-4

Price Negotiable
Price: Negotiable
MOQ: Negotiable
Delivery Time: Negotiable
Product Description

Sunitinib rtk inhibitor C Kit Inhibitors Cas 557795-19-4

 

+ AII PRODUCTS

- Prostaglandins - Custom Synthesis - PARP Inhibitors - PI3K Inhibitors - FAK Inhibitors - AKT Inhibitors - C-Kit Inhibitors - VEGFR Inhibitors - c-Met Inhibitors - CDK Inhibitors - CYP17 Inhibitors - DNA/RNA Inhibitors - mTOR Inhibitors - SRC Inhibitors - Others

Product

Size

Price

Stock

Quantity

Get Quotation Now Add to Cart Bulk Inquiry

 

AddThis Sharing Buttons

Share to FacebookFacebookShare to TwitterTwitterShare to PrintPrintShare to EmailEmailShare to PinterestPinterestShare to GmailGmailShare to LinkedInLinkedInShare to Email AppEmail AppShare to TumblrTumblrShare to MoreAddThis

Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.

 

Chemical Information

Product name:Sunitinib

Purity:98% min

CAS NO:557795-19-4

Solubility:DMSO25 mg/mL (62.74 mM)

Molecular Formula:C22H23D4FN4O2

Package:Package according to customer requirements

Molecular Weight:402.498

Storage:Store at -20℃

 

Quality control

COA

Remarks

Sunitinib free base is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor. Sunitinib malate salt was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) on January 26, 2006. Sunitinib inhibits cellular signaling by targeting multiple receptor tyrosine kinases (RTKs). The simultaneous inhibition of these targets therefore reduces tumor vascularization and triggers cancer cell apoptosis and thus results in tumor shrinkage. Sunitinib also inhibits CD117 (c-KIT), the receptor tyrosine kinase that (when improperly activated by mutation) drives the majority of gastrointestinal stromal cell tumors.

 

Related Products

Pexidartinib hcl; Pexidartinib; Telatinib; Avapritinib; Amuvatinib; DovitinibLactate; Linifanib; OSI-930; Crenolanib; Motesanib Diphosphate; Motesanib; Imatinib mesylate; Axitinib; Masitinib; Dovitinib; ISCK03;Sunitinib Malate

References

Get in Touch

Have questions about our products or want to discuss a custom order? Our team is ready to help you.

Company Taizhou Crene Biotechnology Co., Ltd.
Location Add: Economic Developed Zone of Taizhou Zhejiang China.

Request A Quote

Please check your email address.
Your message must be at least 20 characters.